An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
Sidra Medicine, a member of Qatar Foundation, has established a gene therapy centre to treat rare genetic diseases such as ...
cbc.ca on MSN11d
Man with degenerative disease pleads for Manitoba to cover treatment while it asks drug agency to reviewA man with a muscle-wasting disease is pleased Manitoba is asking a federal agency to reconsider its opposition to a ...
The rate of progression of the muscular dystrophies depends on the type of dystrophy. While some progress slowly, others confine the patient to a wheelchair within a few years. Significant advances in ...
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback